FAGR Fagron SA

Fagron shareholders approve majority voting items

Fagron shareholders approve majority voting items

Regulated information

Nazareth (Belgium)/Rotterdam (The Netherlands), 8 May 2023 – 7 PM CET

Fagron shareholders approve majority voting items

Today, Fagron, the leading global player in pharmaceutical compounding, held its annual general meeting of shareholders. The meeting approved the voting items, with the exemption of the proposal to approve the accelerated vesting in case of a public offer on or a change of control over Fagron as provided for in the Performance Share Plan (agenda item 10). This provision will be deleted from the plan.

Resolutions

The meeting approved, amongst other things, Fagron’s annual financial statements and dividend proposal of €0.25 for the fiscal year 2022, and the remuneration policy. The meeting also approved the proposed appointments.

Composition Board of Directors

Following the approved appointments and the stepping down of Management Deprez BV, represented by Veerle Deprez, the Board of Directors currently consists of the following 8 members: AHOK BV, represented by Mr. Koen Hoffman (chair), Rafael Padilla (CEO), Karin de Jong (CFO), Ann Desender, Els Vandecandelaere LLC, represented by Els Vandecandelaere, Robert ten Hoedt, Neeraj Sharma, and Klaus Röhrig.

Meeting and meeting documents

All meeting documents related to the annual general meeting can be found on the Fagron . The minutes of the meeting will also be made available on the website.

Dividend calendar

The dividend calendar is as follows:

  • Ex-dividend date: 15 May 2023
  • Record date: 16 May 2023
  • Payment date: 17 May 2023

Further information

Karen Berg

Global Investor Relations Manager

Tel. 99

 

About Fagron

Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics, and patients in more than 30 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails. 

Please open the link below for the press release:



EN
08/05/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

 PRESS RELEASE

Disclosure of a transparency notification from AOC Pharma S.à r.l.

Disclosure of a transparency notification from AOC Pharma S.à r.l. Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 27 02 2026 – 6PM CET Disclosure of a transparency notification from AOC Pharma S.à r.l. Pursuant to the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from AOC Pharma S.à r.l., dated 24 February 2026. Notification from AOC Pharma S.à r.l. On 24 February 2026, Fagron received a transparency notification from AOC Pharma S.à r.l., informing the Company that its sharehold...

 PRESS RELEASE

Openbaarmaking van transparantiekennisgeving van AOC Pharma S.à r.l.

Openbaarmaking van transparantiekennisgeving van AOC Pharma S.à r.l. Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 27 februari 2026 – 18:00 CET Openbaarmaking van transparantiekennisgeving van AOC Pharma S.à r.l. Overeenkomstig de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen, ontving Fagron een transparantiekennisgeving van AOC Pharma S.à r.l., gedateerd 24 februari 2026. Kennisgeving van AOC Pharma S.à r.l. Op 24 februari 2026 ontving Fagron een transparantiekennisgeving van AOC Pharma S.à r.l....

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ackermans & van Haaren: Results capping already strong subsidiary reporting. DPS beat. Fagron: Acquisition of Pharmavit Europe, active in nutraceutical raw materials. Fugro: Patience please. Kendrion: Sees signs of improvement in EU economy. Proximus: 2026 dividend halved, 2028-30 targets a bit better on lower capex. Proximus: 4Q25 in line EBITDA on weaker sales, FCF up; 2026 guidance below on EBITDA. Recticel: Strong FY25 results, CEO transition seen as a negative

Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi

Morning Notes : ACKB BB, FAGR BB, FUR NA, MTLS US, MDXH BB, PROX BB, R...

: ACKB BB, FAGR BB, FUR NA, MTLS US, MDXH BB, PROX BB, RECT BB, WHATS BB

 PRESS RELEASE

Fagron completes strategic acquisition of Pharmavit Europe, strengthen...

Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 February 2026 – 6:30PM Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA Fagron, the leading global player in pharmaceutical compounding, announces that it has completed the acquisition of Pharmavit Europe, a leading European distributor of nutraceutical raw material...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch